Royal DSM, a global science-based leader in health, nutrition and bioscience, agreed to acquire Adare Biome, a pioneer in the development and manufacturing of postbiotics, from Adare Pharma Solutions, a global technology-driven CDMO providing end-to-end integrated services, for €275m. “DSM would be the ideal company to take Adare Biome to a new level and realize the growth potential of postbiotics. They have the infrastructure and strong commercialization and science capabilities to scale the significant scientific research achieved over the years and DSM’s mission to create healthier lives for all will resonate strongly with the team,” Tom Sellig, Adare Pharma Solutions CEO.